Drug Therapy for Alcohol Detoxification

NCT ID: NCT00000441

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2000-12-31

Brief Summary

This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.

Conditions

Alcoholism

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

lorazepam (Ativan)

Intervention Type: DRUG

carbamazepine (Tegretol)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Meets criteria for alcohol dependence and uncomplicated alcohol withdrawal syndrome.
• Ability to provide informed consent, complete self-rating questionnaires, and respond to structured clinician-rated instruments.
• Must live within 50 miles or one hour of the study site and have reliable transportation to the site.
• Must have a significant other who will provide a collateral report, attend outpatient visits, and be available by telephone.
• Subjects must be medically stable.
• Must have a clinical withdrawal assessment prior to study.

Exclusion Criteria

• Meets criteria for any other substance dependence syndrome other than alcohol dependence or marijuana abuse.
• Use of other illicit psychoactive substances (except marijuana) in the last 7 days.
• Use of pharmaceutical agents within the last 14 days that are known to lower the seizure threshold, augment or decrease the alcohol withdrawal syndrome.
• History of status epilepticus or two or more seizures occurring within 24- hour period during a previous alcohol withdrawal or other forms of epilepsy.
• Current major depressive illness, dementia, suicidal or homicidal ideation, or past or present schizophrenia.
• Acute medical instability as characterized by hepatic encephalopathy, past or present severe liver failure.
• Diabetes requiring insulin, or severe renal disease.
• Pregnant females.
• High blood pressure.
• Individuals with vomiting who cannot take oral medications at beginning of study or whose vomiting can be controlled only with antiemetic medication.
• High white blood count, or liver function test that is 3 times higher than normal.
• Known hypersensitivity or previous adverse reaction to carbamazepine, lorazepam, or other benzodiazepines.
• Any relevant ECG abnormality which might require hospitalization or greatly interfere with safety during outpatient withdrawal.
• History of severe gastrointestinal (GI) disease which might render absorption of the medication difficult or produce medical instability of the patient during detoxification which would include active peptic ulcer disease, ulcerative colitis, regional ileitis, or evidence by history or physical examination of GI bleeding.
• Familial tremor or other neurological condition, determined by history, known to produce tremor.
• Unable to provide a written informed consent.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role: lead

Locations

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina

Charleston, South Carolina, United States

Countries

United States

Other Identifiers

NIAAAMAL10761

Identifier Type: -

Identifier Source: org_study_id